It never ceases to amaze anti-obesity drug from Novo Nordisk with the active ingredient semaglutide. After the worldwide success of sales and profits, Wegovy* could now become useful in the fight against alcoholism and liver diseases. Novo Nordisk – reports the ‘Financial Times’ – is testing its slimming drugs to see if they can help those with alcohol problems and cure some liver diseases.
Some researchers who have analyzed the effects of semaglutide have reported that, in addition to controlling insulin and blood sugar levels, it can also potentially influence the areas of the brain that regulate our cravings for food, but also alcohol. A report published online in the ‘New York Times’ highlighted that those who take the anti-diabetes drug Ozempic*, also from Novo Nordisk and always with the active ingredient semaglutide, have never touched a glass of wine again. Many clues that have led the Danish pharmaceutical group to focus on this front too.
And in fact Novo Nordisk, reports the Ft, “has started recruitment for a phase II study” which “should end in June 2025”, with the aim of “verifying approximately 240 patients using semaglutide and cagrilintide, the active ingredient of another Novo Nordisk drug in development for weight loss, whether “these molecules” can address liver damage and reduce alcohol consumption in trial participants with alcoholic liver disease. The company is already at work on the obesity-related liver disease front, but this is the first study to evaluate the effectiveness of the new generation of slimming treatments on alcoholic liver disease.”
Semaglutide has shown health benefits beyond weight loss. A recent study showed that could reduce the risk of death in patients with cardiovascular disease by 18%..
#Antiobesity #drug #cures #alcoholism #experimentation
